Canada accused of dumping medical cannabis by Israel

In the global medical cannabis market, the Canada has established itself as a leading figure and an omnipresent actor.

With a long history in the medical cannabis sector, Canadian producers have capitalized on international demand to become a major player in the field. major exporters of medical cannabis, sometimes to the detriment of local players struggling to compete.

Dumping in Israel?

Israel, also known for its research into medical cannabis, is concerned about the impact of Canadian imports on its domestic industry. The Israeli Ministry of Economy has launched an «anti-dumping» investigation into Canadian cannabis companies, following complaints from Israeli growers. The investigation focuses on allegations that low-priced Canadian imports are undercutting local prices, leading to financial losses and market destabilization.

At the heart of the dispute are the pricing strategies of Canadian companies. While medical cannabis is sold at higher prices in Canada, it is reportedly offered at much lower prices when exported to Israel.

This practice, known as dumping, has sparked outrage among Israeli producers, who feel unfairly disadvantaged in their own market. The influx of cheap Canadian imports has led to «falling prices and unfair competition», prompting the Israeli authorities to take action.

In 2022, 84 % of the 24,000 kg of medical cannabis imported by Israel came from Canada.

The investigation put the spotlight on several major Canadian cannabis companies, including Canopy Growth, Tilray and Organigram. These and other companies have been asked to provide information and evidence about their activities and pricing practices. The outcome of the investigation could have a significant impact on Canada's cannabis exports, as Israel remains a major destination for Canadian cannabis products.

Tensions between Canada and Israel highlight wider problems in the global cannabis trade. Despite the growing legalization and acceptance of cannabis around the world, regulatory barriers and protectionist measures continue to impede free trade. While the sale of imported cannabis at reduced prices is not illegal per se, it does raise questions about fair competition and market integrity.

Furthermore, this case highlights the disparities in market access between countries. While Canada enjoys a thriving cannabis industry and exports its products to many countries, including Israel, it maintains strict restrictions on imports. This asymmetry has fueled the frustration of Israeli producers, who are calling for a level playing field on the international market.

The outcome of the investigation remains uncertain, but it is already urging greater transparency and cooperation in the global cannabis trade.